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Abstract 
Background. Cough is a common presenting symptom in patients with idiopathic interstitial 
pneumonia (IIP); it is often disabling, and lacks effective treatment. Studies in animals 
suggest that carcainium chloride, a quaternary derivative of the local anesthetic lidocaine, is 
able to inhibit experimentally induced cough by a mechanism of action distinct from that of 
lidocaine. 
Objective. To determine the effectiveness of aerosolised carcainium chloride (VRP700) in 
controlling cough in patients with IIP. 
Methods:  Eight female patients (mean age 71 years) with IIP were investigated in a double 
blind, randomised, placebo controlled crossover, adaptive contingency study design 
(EudraCT Number 2010-021350-19). The study consisted of a screening visit to assess the 
eligibility of patients, and two separated (48-72 hours) study days. On the two study days, 
patients were randomised to receive either nebulized VRP700 (1.0 mg/kg) on the first study 
visit followed by nebulised placebo (sodium chloride 0.9%) on the second visit, or placebo 
on the first visit followed by VRP700 on the second visit. The primary endpoint was cough 
frequency over a 4-hour assessment period; secondary endpoints were subjective cough-
related level of discomfort as assessed by a visual analogue scale (VAS) and the subjective 
response to treatment as assessed by a quality of life question. Safety (ECG, spirometry, 
urine and blood tests) and adverse events occurring during the trial were also investigated.  
Results. In all patients both VRP700 and placebo decreased cough frequency; however, 
mean decreases in cough frequency after treatment with VRP700 were significantly 
(P<0.001) higher than with placebo. Similarly, mean reductions in VAS score were 
significantly (P<0.001) higher after treatment with VRP 700 compared with placebo. All 
but one patient indicated that they felt better after receiving VRP700. No adverse events 
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were reported during the study, nor were any changes in ECG variables, spirometry, urine 
and blood tests noted.   
Conclusion. The results of this exploratory study indicate that nebulised VRP700 improved 
cough and quality of life in hospitalised IIP patients with no significant side effects. A 
larger trial is warranted to assess these promising results. 
 
Keywords: cough, carcainium chloride, antitussive, idiopathic interstitial pneumonia  
Abbreviations: 
Cph, coughs per hour;  
IIP, idiopathic interstitial pneumonia; 
Cmax, maximum plasma concentration; 
Tmax, time to reach maximum plasma concentration 
VAS, visual analogue scale; 
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1. Introduction 
Chronic cough remains a serious unmet medical need [1,2]. Cough is a nerve reflex 
involving the activation of vagally innervated receptors ultimately resulting in cough motor 
events [3]. Receptors (sensors) implicated in the cough reflex have been found on families 
of both thin myelinated (Aδ) and unmyelinated bronchial and pulmonary C sensory nerve 
fibres [4,5]. Not surprisingly, therefore, local anaesthetics can inhibit coughing presumably 
via inhibition of conduction of these sensory nerve fibers [6], but they are known to 
interfere with other important protective reflexes such as the gag reflex [7], limiting their 
wider use in the clinic. 
Carcainium chloride, that is structurally related to the local anaesthetic lidocaine [8], has 
been reported to reduce cough responses in guinea pigs and rabbits by selective inhibition 
of Aδ fibres when applied topically to the airways, whilst having no inhibitory effect on 
bronchial or pulmonary C-fibres, which were both inhibited by topical lidocaine [9]. To our 
knowledge, this selectivity for Aδ fibres has not been reported so far for other drug classes. 
However, to date no studies investigating the effect of inhaled carcainium chloride on 
cough responses have been reported in humans.  
This pilot study, therefore, aimed to investigate the effectiveness of inhaled carcainium 
chloride (hereafter named VRP700) in controlling cough of patients with idiopathic 
interstitial pneumonia (IIP) [10]. Patients with IIPs were chosen since cough is a distressing 
and disabling symptom of this disease [10].  
 
2. Methods 
2.1 Study design and participants 
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This was a randomised, double blind, crossover, placebo controlled study performed 
according to an adaptive contingency design [11]. We enrolled adult, non-smoking 
inpatients with IIP and refractory chronic cough [12]. We excluded patients who reported 
<1 month respiratory tract infections, who were taking an angiotensin-converting enzyme 
inhibitor, or who had liver or renal dysfunction. Women breastfeeding or of childbearing 
age were also excluded. Written consent was obtained from each patient; the study was 
approved by the Ethics Committee of the Careggi Hospital (EudraCT number 2010-
021350-19). 
2.2 Protocol and Recording Procedures 
After screening, each patient was examined on two separate (48-72 hours) occasions 
(Figure 1). On each occasion, patients randomly inhaled 1.0 mg/kg VRP700 or placebo 
(sodium chloride 0.9%) by means of a DeVilbissUltraNeb 3000 nebuliser set to produce 2 
mL/min of aerosol. Administration continued until nebulisation occurred; a ~1.2 ml residue 
remained in the nebuliser cup after each nebulisation. After study completion, patients were 
followed up for a further 12-24 hr. On all occasions, the cough frequency was recorded at 
baseline and for 4 hour after the completion of each inhalation period by means of a cough 
recorder (PulmoTrack® 2010 W-Holter, Karmelsonic) [13] and expressed as coughs per 
hour (cph). Cough-related level of discomfort was investigated by a 10-cm visual analogue 
scale (VAS), with the extremes indicating no discomfort (0 cm) or extreme discomfort (10 
cm). Patients’ subjective response to treatments was also assessed 4 hours post treatment 
asking the patients: “how do you feel: worse, same or better following treatment?” 
Similarly, physicians’ judgement (i.e. superior, same, inferior) of individual patient 
responses in terms of anti-tussive actions compared to baseline was also obtained. Vital 
signs, ECG and spirometry variables were recorded at baseline and 15, 20, 40, 60, 90, 120 
minutes, 3 and 4 hours after drugs administration. Concomitant medication changes and 
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adverse events were reported. Blood and urine samples were collected for standard safety 
laboratory assessments; blood samples were also taken at baseline, at 20, 40, 60, 90, 120 
minutes and 3, 4 hours after VRP700 inhalation to calculate the maximum plasma 
concentration (Cmax) and time to reach Cmax (Tmax) [14].  
2.4 Data Analysis 
The primary outcome variable was cough frequency over a 4-hour assessment period 
measured before and after VRP700 and placebo administration; secondary outcome 
variables were VAS scores, patients’ subjective response and physicians’ judgement. 
Categorical data were expressed as percentages, whereas normal distributed data were 
presented as mean ±SD. For efficacy parameters, all tests for a difference between the two 
treatments have been two-sided and performed at the 5% significance level.  
 
3. Results 
Eight female patients (Table) completed the study with no significant changes in vital 
signs, ECG variables, spirometry, as well as in any parameters measured in blood or urine. 
Preliminary CT scans indicated that six patients suffered from usual interstitial pneumonia, 
one had non-specific interstitial lung disease, and another one had an unclassifiable IIP. No 
patients reported adverse events during the study. However, they consistently coughed more 
during the 1st or 2nd minutes of nebulisation of active drug, followed by a marked decrease 
in cough over the rest of nebulisation period. As the cough monitor was not started until 
after inhalation had completed, these initial coughs have not been recorded.  
In the patients as a group, Cmax for VRP700 ranged from 2.26 to 37.7 ng/mL with a Tmax 
of 20 min. 
VRP700 significantly decreased cough frequency from 57.75±15.51 cph to 13.13±9.62 
cph four hours after VRP700 administration (p<0.001, Figure 2). With placebo, the same 
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variable decreased from 46.06±10.70 cph to 37.38±19.34 cph (NS). Comparisons of mean 
decreases in cough frequency with VRP 700 and placebo demonstrated a much higher 
reduction (P<0.001) in cough frequency with the active drug rather than with placebo 
(Figure 1). 
In all patients, VRP700 reduced (P<0.001) baseline VAS scores with an overall mean 
reduction of 5.60±0.90. For the placebo treatment, in four patients the post-placebo values 
were lower than the pre-placebo values with an overall mean reduction of 1.8±1.0 (Figure 
2). As with cough frequency, comparisons of mean changes in VAS score with VRP 700 
and placebo demonstrated a significantly (P<0.001) higher reduction in VAS score with the 
active drug rather than with placebo (Figure 2). Scrutiny of data (Figure 2) indicated that in 
4 patients treated with the sequence VRP700-placebo, the cough frequency values and VAS 
scores were smaller after placebo than after the reverse sequence. 
All patients indicated that they felt better after receiving VRP700. Only 1 patient felt 
better after receiving placebo and one felt worse: the remaining patient reported no 
appreciable change; so that the difference between the 2 treatments was statistically 
significant (P<0.02 by Chi squared). In all patients, physicians selected VRP700 as being 
the more effective (P<0.01) treatment in reducing the patient’s cough frequency. 
 
4. Discussion 
We have demonstrated a marked antitussive effect of nebulised VRP700 in patients with 
chronic cough and IIP with an overall 80% reduction in cough frequency. Patients also 
reported a remarkable subjective improvement, also confirmed by medical evaluation. 
VRP700 appears to be safe since none of the patients reported any clinically relevant side 
effect, notably no paraesthesia that has been reported following treatment with local 
anaesthetics. 
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One limitation of the crossover study design is the so-called carry over effect [15]. 
Indeed, four patients showed a larger reduction in cough frequency and VAS score when 
they received the sequence VRP700-placebo rather than the sequence placebo-VRP700, 
thus suggesting that prior exposure to the active drug may have enhanced the subsequent 
responses to placebo. However, overall, the active drug proved to be far more effective than 
placebo in the patients as a group, although there were insufficient samples to test for 
statistical significance of the sequence effect in the study population. On the other hand, the 
advantage of the statistical method used here [11] is that it does not require an initial 
commitment to a large sample size, since the ultimate sample size was determined by the 
data generated during the study. 
The reason for female patients being studied reflected that patient recruitment was 
consecutive, and the greater severity of the disease in females [16] may have contributed.  
The exact mechanism(s) underlying cough in IIP remains unclear [17]. For instance, 
more than 50% of patients with interstitial lung disease could have cough caused by other 
causes such as asthma, rhinitis or gastro-oesophageal reflux [18,19]. However, IIP may 
directly cause cough as inflammation is not limited to the parenchyma, and disrupted 
airway epithelium [20] with inflammatory mediators known to provoke cough having been 
detected in such patients [17,18]. A further possible cause of cough in patients with IIP is 
airway distortion secondary to interstitial fibrosis, which results in traction bronchiectasis 
[21]. 
Whilst the molecular mechanism of action of VRP700 remains incompletely understood, 
this is highly unlikely to be due to any local anaesthetic activity of this drug as it has a 
distinct electrophysiological profile from lidocaine on airway sensory nerves [9]. In 
addition, VRP700 inhibits the activation of airway Aδ fibres selectively [9], a finding in 
keeping with a major role for Aδ fibres in many patients with chronic cough. 
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The antitussive effect of VRP700 is comparable to that recently reported using a P2X3 
purinergic receptor antagonist (AF-219) in patients with refractory chronic cough [22]. 
However, unlike AF-219, which was associated with loss of taste in the majority of 
patients, VRP700 was not associated with any major side effects.  
In conclusion, VRP700 may be promising and safe in patients with IIP. Whether the 
drug is also suitable for long-term administration and in the management of patients with 
intractable cough of different origin remains to be ascertained. 
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Captions to the figures 
Figure 1. Study flow chart. PK, pharmacokinetic; See text for details  
Figure 2. Individual values of cough frequency (upper panel) and visual analogue 
scale (VAS) score (lower panel) recorded pre and post drug or placebo 
administration. Bars represent median values.  
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table. Patients ‘characteristics. 
Pt. 
no. 
Sex Age 
(years) 
BMI FEV1 
(% pred.) 
FVC 
(% pred.) 
TLC 
(% pred.) 
DLCO 
(% pred.) 
Main ongoing 
treatment 
 
1 F 75 27.07 63 60 62 49 OCS, PPI, N-ACC 
2 F 79 27.00 NA NA NA NA OCS, PPI, N-ACC 
3 F 75 30.05 88 90 80 65 PPI, N-ACC 
4 F 75 28.00 70 64 65 59 OCS, PPI 
5 F 56 23.15 88 91 99 70 OCS 
6 F 69 36.10 81 76 61 32 OCS, PPI,Ox 
7 F 68 33.01 80 82 77 60 OCS, PPI,Ox, N-ACC 
8 F 71 29.00 66 66 64 48  
 
Mean  --- 71.00 28.00 76.57 75.57 72.57 54.71  
SD  7.07 1.00 10.26 12.62 13.84 12.78  
 
BMI, body mass index;  DLCO, diffusing lung capacity; FEV1, forced expiratory volume at 1 sec; FVC, forced vital 
capacity; NA, not available; N-ACC, N-Acetylcysteine; OCS, oral corticosteroids; Ox, oxygen; Pt, patient; PPI, 
proton pump inhibitors; pred, predicted value; TLC, total lung capacity;. 
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